Literature DB >> 28593708

Age 80 years and over is not associated with increased morbidity and mortality following pancreaticoduodenectomy.

Sandy Y Kim1, Michael A Fink1, Marcos Perini2, Nezor Houli1, Laurence Weinberg2, Vijayaragavan Muralidharan1, Graham Starkey1, Robert M Jones1, Christopher Christophi1, Mehrdad Nikfarjam1.   

Abstract

BACKGROUND: Pancreaticoduodenectomy (PD) is associated with high morbidity, which is perceived to be increased in the elderly. To our knowledge there have been no Australian series that have compared outcomes of patients over the age of 80 undergoing PD to those who are younger.
METHODS: Patients who underwent PD between January 2008 and November 2015 were identified from a prospectively maintained database.
RESULTS: A total of 165 patients underwent PD of whom 17 (10.3%) were aged 80 or over. The pre-operative health status, according to American Society of Anesthesiologists class was similar between the groups (P = 0.420). The 90-day mortality rates (5.9% in the elderly and 2% in the younger group; P = 0.355) and the post-operative complication rates (64.7% in the elderly versus 62.8% in the younger group; P = 0.88) were similar. Overall median length of hospital stay was also similar between the groups, but older patients were far more likely to be discharged to a rehabilitation facility than younger patients (47.1 versus 12.8%; P < 0.0001). Older patients with pancreatic adenocarcinoma (n = 10) had significantly lower median survival than the younger group (n = 69) (16.6 versus 22.5 months; P = 0.048).
CONCLUSION: No significant differences were seen in the rate of complications following PD in patients aged 80 or over compared to younger patients, although there appears to be a shorter survival in the elderly patients treated for pancreatic cancer. Careful selection of elderly patients and optimal peri-operative care, rather than age should be used to determine whether surgical intervention is indicated in this patient group.
© 2017 Royal Australasian College of Surgeons.

Entities:  

Keywords:  aged 80 or over; octogenarian; pancreas; pancreaticoduodenectomy; post-operative outcome

Mesh:

Year:  2017        PMID: 28593708     DOI: 10.1111/ans.14039

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN: 1445-1433            Impact factor:   1.872


  5 in total

1.  Does Major Pancreatic Surgery Have Utility in Nonagenarians with Pancreas Cancer?

Authors:  Rebecca S Meltzer; David A Kooby; Jeffrey M Switchenko; Jashodeep Datta; Darren R Carpizo; Shishir K Maithel; Mihir M Shah
Journal:  Ann Surg Oncol       Date:  2020-11-03       Impact factor: 5.344

2.  Nutritional assessment and surgical outcomes in very elderly patients undergoing pancreaticoduodenectomy: a retrospective study.

Authors:  Masashi Utsumi; Hideki Aoki; Seiichi Nagahisa; Yuta Une; Yuji Kimura; Megumi Watanabe; Fumitaka Taniguchi; Takashi Arata; Koh Katsuda; Kohji Tanakaya
Journal:  Surg Today       Date:  2020-10-26       Impact factor: 2.549

Review 3.  Anesthetic management of geriatric patients.

Authors:  Byung-Gun Lim; Il-Ok Lee
Journal:  Korean J Anesthesiol       Date:  2019-10-22

4.  Short- and Long-Term Outcomes of Pancreatic Cancer Resection in Elderly Patients: A Nationwide Analysis.

Authors:  I Quintus Molenaar; Hjalmar C van Santvoort; Anne Claire Henry; Thijs J Schouten; Lois A Daamen; Marieke S Walma; Peter Noordzij; Geert A Cirkel; Maartje Los; Marc G Besselink; Olivier R Busch; Bert A Bonsing; Koop Bosscha; Ronald M van Dam; Sebastiaan Festen; Bas Groot Koerkamp; Erwin van der Harst; Ignace H J T de Hingh; Geert Kazemier; Mike S Liem; Vincent E de Meijer; Vincent B Nieuwenhuijs; Daphne Roos; Jennifer M J Schreinemakers; Martijn W J Stommel
Journal:  Ann Surg Oncol       Date:  2022-06-02       Impact factor: 4.339

5.  Short- and long-term outcomes of pancreaticoduodenectomy in elderly patients with periampullary cancer.

Authors:  Jae Seung Kang; Hongbeom Kim; Jae Ri Kim; Youngmin Han; Eunjung Kim; Yoonhyeong Byun; Yoo Jin Choi; Wooil Kwon; Jin-Young Jang; Sun-Whe Kim
Journal:  Ann Surg Treat Res       Date:  2019-12-30       Impact factor: 1.859

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.